1.7 mg Wegovy Not Working: What's Actually Happening at This Dose

Step 1: Recognise where 1.7 mg sits in the escalation sequence

Wegovy is prescribed on a slow-escalation schedule for a reason. You start at 0.25 mg, then move through 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, spending roughly four weeks at each level. The full Wegovy dose schedule exists primarily to give your body time to adjust, the graduated steps reduce the nausea and other gastrointestinal effects that can hit hard if you jump straight to a high dose.

What this means practically: 1.7 mg is the penultimate step. It is not where the medicine was designed to stay. The pivotal clinical evidence for Wegovy comes mostly from participants who had completed the full titration and reached 2.4 mg. Judging the treatment's effectiveness at 1.7 mg is a bit like reviewing a book after reading only the penultimate chapter. That doesn't mean 1.7 mg produces no effect (many people do see measurable loss here) but it does mean the comparison point you may have in mind (those well-reported trial averages) belongs to a different point in the journey.

If you have recently moved up from 1 mg and haven't yet seen much change, give the dose a full four-week cycle before drawing conclusions. The experience at 1 mg is often similarly frustrating for the same reason.

Step 2: Check whether your expectations match the evidence

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4 mg for 68 weeks. Average weight loss across that period was around 15% of body weight, but the weight did not fall in a straight line. Most participants lost relatively little in the first few months and then lost more steadily through the middle and later stages of the trial. Week 12 or 16, which is approximately where many people find themselves on 1.7 mg, is often still in the early-returns phase.

It's also worth separating two different questions: is my appetite genuinely unchanged, or is it reduced but my eating hasn't changed yet? Semaglutide works partly by slowing gastric emptying and partly by acting on hunger-signalling pathways in the brain. Some people describe a clear drop in appetite almost immediately after a dose increase; others barely notice the appetite shift at all but find, on reflection, that they've been eating less. The scale doesn't always reflect either in the short term because of water retention, hormonal fluctuations, or simply the natural variation in body weight day to day.

The full Wegovy overview covers the mechanism and evidence base in more detail if you want the broader picture.

Step 3: Consider what else might be blunting the effect

A number of factors genuinely influence how much weight someone loses on semaglutide, independent of the dose. None of them mean the medicine is failing you, but they are worth being honest about.

Diet composition matters more than calorie-counting alone. High-fat, high-sugar foods can to some degree work against the appetite suppression the medicine creates, not by blocking the drug, but by driving a reward-based eating pattern that the GLP-1 pathway doesn't fully suppress. Sleep deprivation raises hunger hormones in ways that can partially offset semaglutide's appetite-lowering effect. Alcohol provides calories without any satiety signal and can reduce commitment to food choices the next day. Physical activity isn't required for weight loss on this medicine, but it does affect body composition and metabolism in ways that influence what the scales say.

If you're concerned about how cost might factor into your longer-term decision on treatment, the Wegovy pricing page covers what private treatment typically involves in the UK. Worth having the full picture before making any changes.

Individual variability in how people metabolise semaglutide is also real. Some people are slow responders who go on to lose significant weight; some genuinely respond better to a different medicine. This is exactly the kind of question a prescriber should be helping you think through, not one to resolve by stopping treatment unilaterally.

Step 4: Know when to speak to your prescriber

If you've been on 1.7 mg for a full four-week period, your appetite hasn't changed at all, you're not losing any weight, and you have no significant side effects that would explain reduced absorption, that's a conversation for your prescriber. It is not a reason to stop taking the medicine or to adjust your dose yourself.

The licensed criteria say that if someone has not lost at least 5% of their body weight after six months on the maintenance dose, continuing treatment should be reviewed. Note the specifics there: six months, maintenance dose (2.4 mg), not a mid-titration step. So if you're at 1.7 mg and three months in, the clinical clock hasn't even started in the way that guidance describes. The NHS semaglutide information page has a clear summary of what to expect and when to contact a healthcare professional.

Some people who genuinely don't respond to semaglutide go on to do well on tirzepatide (Mounjaro), which works on two appetite-related receptors rather than one. If you're at a point where you and a prescriber are genuinely reassessing, that's worth exploring through a proper consultation. The picture at 2.4 mg is the relevant reference point for a full response assessment, if you haven't reached that dose yet, you haven't had the full trial. Similarly, if you've had doubts earlier in the journey, the patterns at the first dose are worth understanding as context. If you'd like a prescriber at nume to review where you are, start your free consultation and one of our GPhC-registered Independent Prescribers will read your case the same day, a real clinician, not a screening algorithm.